Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) antibody and antigen (Recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-CYFRA21-1-Ag01	Recombinant human KRT19/CYFRA21-1 Protein	3090
GMP-h-CYFRA21-1-Ab01	Anti-human KRT19/CYFRA21-1 mouse monoclonal antibody (mAb)	1953
GMP-h-CYFRA21-1-Ab02	Anti-human KRT19/CYFRA21-1 mouse monoclonal antibody (mAb)	1953
GMP-h-CYFRA21-1-Ab03	Anti-human KRT19/CYFRA21-1 human monoclonal antibody (mAb)	1953
GMP-h-CYFRA21-1-Ab04	Anti-human KRT19/CYFRA21-1 human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-h-CYFRA21-1-Ag01
Product Name	Recombinant human KRT19/CYFRA21-1 Protein
Target/Biomarker	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)
Alias of Target/Biomarker	CK19, K19, K1CS
Expression platform	mammalian
Isotypes	Recombinant Antigen
Bioactivity validation	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYFRA21-1 level test of Cancer (bronchopulmonary dysplasia) and related syndrome evaluation.
Tag	His
Products description	Recombinant human KRT19/CYFRA21-1 Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-CYFRA21-1-Ab01, GMP-h-CYFRA21-1-Ab02
Product Name	Anti-human KRT19/CYFRA21-1 mouse monoclonal antibody (mAb)
Target/Biomarker	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)
Alias of Target/Biomarker	CK19, K19, K1CS
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYFRA21-1 level test of Cancer (bronchopulmonary dysplasia) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human KRT19/CYFRA21-1 mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-CYFRA21-1-Ab03, GMP-h-CYFRA21-1-Ab04
Product Name	Anti-human KRT19/CYFRA21-1 human monoclonal antibody (mAb)
Target/Biomarker	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)
Alias of Target/Biomarker	CK19, K19, K1CS
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYFRA21-1 level test of Cancer (bronchopulmonary dysplasia) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human KRT19/CYFRA21-1 human monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

CYRFA 21-1 (cytokeratin 19 fragment) has been demonstrated as clinically useful in the prognostication and monitoring of non-small cell lung cancer (NSCLC). Elevated pretreatment levels may be associated with unfavorable prognosis, and decreasing levels during therapy predict an objective response to treatment. CYFRA 21–1 is a cytoplasmic protein fragment of cytokeratin 19 (CK-19) which is found in various epithelial malignancies, such as lung cancer[, gastrointestinal cancer and cervical cancer. This soluble debris can be released into the blood after tumor cell death, thus exhibiting a close relationship with tumor cell necrosis. Its level could be a proper indicator of necrosis degree. It has been reported that CYFRA 21–1 is a potential tumor marker for the diagnosis and prognosis of non-small cell lung cancer (NSCLC) and squamous carcinoma of the head and neck. Other studies have confirmed that the serum CYFRA 21–1 level before treatment is related to poor prognosis in patients with non-metastatic head and neck cancer (HNC).

About GDU